Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas

Hio Chung Kang, Hong Kwan Kim, Sharon Lee, Pedro Mendez, James Wansoo Kim, Gavitt Woodard, Jun Hee Yoon, Kuang-Yu Jen, Li Tai Fang, Kirk Jones, David M. Jablons, Il Jin Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood. Genetic alterations and causes for multiple primary cancer development including MPM are unknown. We used whole exome sequencing to identify somatic mutations in a patient with MPM and two additional primary cancers who had no evidence of venous, arterial, lymphovascular, or perineural invasion indicating dissemination of a primary lung cancer to the pleura. We found that the MPM had R282W, a key TP53 mutation, and genome-wide allelic loss or loss of heterozygosity, a distinct genomic alteration not previously described in MPM. We identified frequent inactivating SETDB1 mutations in this patient and in 68 additional MPM patients (mutation frequency: 10%, 7/69) by targeted deep sequencing. Our observations suggest the possibility of a new genetic mechanism in the development of either MPM or multiple primary cancers. The frequent SETDB1 inactivating mutations suggest there could be new diagnostic or therapeutic options for MPM.

Original languageEnglish (US)
Pages (from-to)8321-8331
Number of pages11
JournalOncotarget
Volume7
Issue number7
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Exome
High-Throughput Nucleotide Sequencing
Loss of Heterozygosity
Genome
Mutation
Neoplasms
Malignant Mesothelioma
Pleura
Asbestos
Mutation Rate
Lung Neoplasms

Keywords

  • Exome sequencing
  • Genome-wide allelic loss
  • Malignant pleural mesothelioma
  • Multiple primary cancer
  • SETDB1

ASJC Scopus subject areas

  • Oncology

Cite this

Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. / Kang, Hio Chung; Kim, Hong Kwan; Lee, Sharon; Mendez, Pedro; Kim, James Wansoo; Woodard, Gavitt; Yoon, Jun Hee; Jen, Kuang-Yu; Fang, Li Tai; Jones, Kirk; Jablons, David M.; Kim, Il Jin.

In: Oncotarget, Vol. 7, No. 7, 01.01.2016, p. 8321-8331.

Research output: Contribution to journalArticle

Kang, HC, Kim, HK, Lee, S, Mendez, P, Kim, JW, Woodard, G, Yoon, JH, Jen, K-Y, Fang, LT, Jones, K, Jablons, DM & Kim, IJ 2016, 'Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas', Oncotarget, vol. 7, no. 7, pp. 8321-8331. https://doi.org/10.18632/oncotarget.7032
Kang, Hio Chung ; Kim, Hong Kwan ; Lee, Sharon ; Mendez, Pedro ; Kim, James Wansoo ; Woodard, Gavitt ; Yoon, Jun Hee ; Jen, Kuang-Yu ; Fang, Li Tai ; Jones, Kirk ; Jablons, David M. ; Kim, Il Jin. / Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. In: Oncotarget. 2016 ; Vol. 7, No. 7. pp. 8321-8331.
@article{3de59850bc1e490087ba676ffe6d2de2,
title = "Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas",
abstract = "Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood. Genetic alterations and causes for multiple primary cancer development including MPM are unknown. We used whole exome sequencing to identify somatic mutations in a patient with MPM and two additional primary cancers who had no evidence of venous, arterial, lymphovascular, or perineural invasion indicating dissemination of a primary lung cancer to the pleura. We found that the MPM had R282W, a key TP53 mutation, and genome-wide allelic loss or loss of heterozygosity, a distinct genomic alteration not previously described in MPM. We identified frequent inactivating SETDB1 mutations in this patient and in 68 additional MPM patients (mutation frequency: 10{\%}, 7/69) by targeted deep sequencing. Our observations suggest the possibility of a new genetic mechanism in the development of either MPM or multiple primary cancers. The frequent SETDB1 inactivating mutations suggest there could be new diagnostic or therapeutic options for MPM.",
keywords = "Exome sequencing, Genome-wide allelic loss, Malignant pleural mesothelioma, Multiple primary cancer, SETDB1",
author = "Kang, {Hio Chung} and Kim, {Hong Kwan} and Sharon Lee and Pedro Mendez and Kim, {James Wansoo} and Gavitt Woodard and Yoon, {Jun Hee} and Kuang-Yu Jen and Fang, {Li Tai} and Kirk Jones and Jablons, {David M.} and Kim, {Il Jin}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.7032",
language = "English (US)",
volume = "7",
pages = "8321--8331",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "7",

}

TY - JOUR

T1 - Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas

AU - Kang, Hio Chung

AU - Kim, Hong Kwan

AU - Lee, Sharon

AU - Mendez, Pedro

AU - Kim, James Wansoo

AU - Woodard, Gavitt

AU - Yoon, Jun Hee

AU - Jen, Kuang-Yu

AU - Fang, Li Tai

AU - Jones, Kirk

AU - Jablons, David M.

AU - Kim, Il Jin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood. Genetic alterations and causes for multiple primary cancer development including MPM are unknown. We used whole exome sequencing to identify somatic mutations in a patient with MPM and two additional primary cancers who had no evidence of venous, arterial, lymphovascular, or perineural invasion indicating dissemination of a primary lung cancer to the pleura. We found that the MPM had R282W, a key TP53 mutation, and genome-wide allelic loss or loss of heterozygosity, a distinct genomic alteration not previously described in MPM. We identified frequent inactivating SETDB1 mutations in this patient and in 68 additional MPM patients (mutation frequency: 10%, 7/69) by targeted deep sequencing. Our observations suggest the possibility of a new genetic mechanism in the development of either MPM or multiple primary cancers. The frequent SETDB1 inactivating mutations suggest there could be new diagnostic or therapeutic options for MPM.

AB - Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood. Genetic alterations and causes for multiple primary cancer development including MPM are unknown. We used whole exome sequencing to identify somatic mutations in a patient with MPM and two additional primary cancers who had no evidence of venous, arterial, lymphovascular, or perineural invasion indicating dissemination of a primary lung cancer to the pleura. We found that the MPM had R282W, a key TP53 mutation, and genome-wide allelic loss or loss of heterozygosity, a distinct genomic alteration not previously described in MPM. We identified frequent inactivating SETDB1 mutations in this patient and in 68 additional MPM patients (mutation frequency: 10%, 7/69) by targeted deep sequencing. Our observations suggest the possibility of a new genetic mechanism in the development of either MPM or multiple primary cancers. The frequent SETDB1 inactivating mutations suggest there could be new diagnostic or therapeutic options for MPM.

KW - Exome sequencing

KW - Genome-wide allelic loss

KW - Malignant pleural mesothelioma

KW - Multiple primary cancer

KW - SETDB1

UR - http://www.scopus.com/inward/record.url?scp=84958824957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958824957&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7032

DO - 10.18632/oncotarget.7032

M3 - Article

C2 - 26824986

AN - SCOPUS:84958824957

VL - 7

SP - 8321

EP - 8331

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 7

ER -